NIH NIAID Infectious Diseases Clinical Trials Network (IDCTN) – RFA-AI-27-002

The National Institute of Allergy and Infectious Diseases (NIAID) is accepting applications for the Infectious Diseases Clinical Trials Network (IDCTN) under RFA-AI-27-002. The network will support Clinical Trial Evaluation Units (CTEUs) and one Network Coordination Center (NCC) to evaluate therapeutics, vaccines, biologics, diagnostics, and devices for emerging and chronic infectious diseases.

NIAID intends to commit up to $10 million in FY 2027 for 7 to 11 CTEU awards and one CTEU award that includes the sole NCC. CTEU budgets may request up to $450,000 in direct costs per year; an application that includes the NCC may request an additional $2 million in direct costs per year. The project period is seven years and no cost share is required.

Eligible domestic applicants include higher education institutions, nonprofits, for-profit organizations including small businesses, state and local governments, Tribal governments and organizations, independent school districts, and other listed U.S. entities. At least one PD/PI must be an M.D. or D.O. Required registrations include SAM/UEI, Grants.gov, eRA Commons, and ORCID for PD/PIs. Foreign organizations are not eligible, and the NOFO states that funded foreign subawards or subcontracts are not permitted.

Deadline: Applications are due November 10, 2026 at 5:00 PM local time of the applicant organization. The earliest submission date is October 10, 2026.

Atlas rates the Nonagon N9+ fit at 55/100. There is a legitimate potential research or vendor role because the NOFO expressly includes diagnostics and devices, but any use must be tied to an approved infectious-disease protocol and satisfy applicable FDA, GCP, IRB, data, and site-infrastructure requirements. Dr. Miltie should not be treated as the prime applicant unless it can independently satisfy the full CTEU infrastructure requirements.